Under construction – not a live service
Sign in
Not yet taking people in ArgentinaNo phase

Testing a score to skip extra biopsy samples in prostate cancer diagnosis

Checks whether a score can show when extra prostate biopsy samples are unnecessary.

Plain-language title generated from the registry record
Registry title: VALIDATION OF FUSION CEMEP SCORE FOR OMITTING SYSTEMATIC PROSTATE BIOPSY

Key facts

Where
Rio Grande, ArgentinaSee the site

Where in Argentina

  • Clinica CemepRio Grande, ArgentinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Marcelo Ruben Oliva
Trial code
NCT07753356
Record updated
7 August 2026
Original description
This study aims to prospectively validate the Fusion CEMEP score to assess the safety and efficacy of omitting systematic prostate biopsy in patients undergoing multiparametric magnetic resonance imaging-targeted biopsy. The main objective is to determine if target-only biopsy guided by the score is sufficient for clinically significant prostate cancer detection while reducing overtreatment and unnecessary cores.Read full original descriptionShow less

VALIDATION OF THE FUSION CEMEP SCORE FOR THE OMISSION OF SYSTEMATIC PROSTATE BIOPSY IN PATIENTS UNDERGOING MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING-TARGETED BIOPSY

This study aims to prospectively validate the Fusion CEMEP score to assess the safety and efficacy of omitting systematic prostate biopsy in patients undergoing multiparametric magnetic resonance imaging-targeted biopsy. The main objective is to determine if target-only biopsy guided by the score is sufficient for clinically significant prostate cancer detection while reducing overtreatment and unnecessary cores.

Inclusion: Adult male patients with clinical suspicion of prostate cancer; Patients scheduled to undergo multiparametric MRI-targeted prostate biopsy; Signed informed consent.

Exclusion: Prior treatment for prostate cancer; Contraindications to prostate biopsy or multiparametric MRI.

ClinicalTrials.gov NCT07753356